← Back to Search

Monoclonal Antibodies

BCG for Bladder Cancer (OU-SCC-ABC Trial)

Phase 1 & 2
Waitlist Available
Led By Kelly Stratton, MD
Research Sponsored by University of Oklahoma
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights

Summary

This trial tests a combination of avelumab and BCG in patients with recurrent bladder cancer. The treatment aims to boost the immune system to help it find and destroy cancer cells. Avelumab is a type of medication that has been studied for its effects on bladder cancer.

Eligible Conditions
  • Bladder Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Percent of Patients With Complete Response
Percent of Patients With Recurrence Free Survival
Proportion of Patients Receiving Complete Induction Course
+3 more

Side effects data

From undefined Phase 2 trial • 149 Patients • NCT02062580
13%
Cough
13%
Rash- nonspecific
10%
Diaper Rash
8%
Fever
6%
Blocked nostrils
3%
HIV infection
100%
80%
60%
40%
20%
0%
Study treatment Arm
Delayed BCG
Early BCG

Trial Design

1Treatment groups
Experimental Treatment
Group I: BCG + AvelumabExperimental Treatment2 Interventions
Combination of avelumab and intravesical BCG. One cycle = 12 weeks (84 days). A standard maintenance therapy regimen will be provided with BCG occurring at Month 3, 6, and 12. Avelumab treatment ends at the conclusion of Month 12 maintenance therapy.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Avelumab
2017
Completed Phase 2
~2440
BCG
2015
Completed Phase 4
~3220

Find a Location

Who is running the clinical trial?

University of OklahomaLead Sponsor
466 Previous Clinical Trials
91,205 Total Patients Enrolled
EMD SeronoIndustry Sponsor
144 Previous Clinical Trials
27,705 Total Patients Enrolled
Kelly Stratton, MDPrincipal InvestigatorStephenson Cancer Center
1 Previous Clinical Trials
12 Total Patients Enrolled
~3 spots leftby Oct 2025